Maravai LifeSciences Holdings Inc at Nasdaq Investor Conference (Virtual) Transcript
Hello, everyone, and good morning. My name is Tejas Savant, and I'm the Life Sciences Analyst here at Morgan Stanley. It's my pleasure today to host a fireside chat with Kevin Herde, CFO of Maravai. Kevin, thanks for doing this.
Before we begin, just have a quick disclosure statement to rattle off here, for important disclosures, please see the Morgan Stanley research website at morganstanley.com/researchdisclosures. And if you have any questions, do reach out to your sales rep.
Questions & Answers
So Kevin, perhaps just to set the stage, for folks on the call, who are not as familiar with the Maravai story. Could you just provide an overview of the portfolio? And what do you think is your competitive differentiation across each of the segments?
Yes, absolutely. So first of all,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |